Download PDF
CC BY 4.0 · J Pediatr Infect Dis 2024; 19(02): 065-074
DOI: 10.1055/s-0043-1777092
Original Article

Effects of EPs 7630 on Illness Absence from Childcare or School due to Acute Bronchitis—A Meta-analysis

Karl Zwiauer
1   Department of Pediatrics, Karl Landsteiner University of Health Sciences, Sankt Pölten, Austria
,
Petra Funk
2   Research and Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
,
Andrea Zimmermann
2   Research and Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
,
Walter Lehmacher
3   Emeritus, Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany
,
Wolfgang Kamin
4   Children's Hospital, Evangelic Hospital, Hamm, Germany
5   Faculty of Medicine, Pomeranian Medical University, Szczecin, Poland
› Author Affiliations Funding This study and its publication were funded by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective In the pediatric population, acute bronchitis (AB) is a leading cause of illness absence from childcare, school, or apprenticeship. We report a meta-analysis of double-blind, randomized trials with children and adolescents with AB (aged 1–18 years), who were treated with Pelargonium extract EPs 7630 or placebo for 7 days.

Methods The average number of days absent from childcare, school, or apprenticeship due to illness and the proportion of patients still unable to return to their normal activities at treatment end were assessed.

Results Literature search identified two eligible trials with a total of 420 patients. Illness absence was reported for all but two patients under placebo at baseline and for 46.7% (EPs 7630) and 85.0% (placebo) of patients at day 7. Meta-analysis risk ratio for absence at day 7 was 0.55 (95% confidence interval: 0.47, 0.64) for all patients, 0.59 (0.46, 0.76) for children younger than 6 years, and 0.53 (0.44, 0.64) for participants aged 6 to 18 years, all favoring EPs 7630. Compared with placebo, average time until return to normal activities was reduced by EPs 7630 by 1.51 (1.16, 1.86) days for all subjects, by 1.50 (0.92, 20.7) days for those younger than 6 years, and by 1.54 (1.11, 1.97) days for those 6 to 18 years of age (p < 0.001 favoring EPs 7630 for all treatment group comparisons shown).

Conclusion For children and adolescents with AB, meta-analysis shows that EPs 7630 treatment for 7 days significantly reduces the average time of illness absence and significantly increases the proportion of patients able to return to normal activities within 1 week.

Keywords

acute bronchitis - adolescent - child - Pelargonium - extracts

Availability of Data and Material

Due to ethical reasons and in terms of data protection law, raw data cannot be shared. To the extent permitted by law, trial data required for validation purposes are already disclosed in results reports on corresponding databases. All relevant data are within the article. Reasonable requests to access the datasets should be directed to the corresponding author.


Ethical Approval and Consent to Participate

All clinical trials included in this meta-analysis were reported to adhere to the principles of Good Clinical practice and the Declaration of Helsinki. The trial protocols and other trial documents required were approved by the respective independent ethics committee and competent authorities. All participants of the single trials gave their informed consent or informed consent was provided by their legal representative, respectively.


Authors' Contribution

K.Z. and W.L. were involved in drafting the manuscript, made substantial contributions to the interpretation of data, revised the work critically for important intellectual content, and approved the version to be published. P.F. was involved in the conceptualization of the study design and medical writing, made substantial contributions to the interpretation of data, revised the work critically for important intellectual content, and approved the version to be published. A.Z. was involved in the conceptualization of the study design and the analysis of data, made substantial contributions to the interpretation of data, revised the work critically for important intellectual content, and approved the version to be published. W.K. was involved in drafting the manuscript, made substantial contributions to the interpretation of data, revised the work critically for important intellectual content, and approved the version to be published.




Publication History

Received: 12 June 2023

Accepted: 17 October 2023

Article published online:
12 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons. J Infect Dis 2014; 210 (11) 1792-1799
    CrossrefPubMedGoogle Scholar
  • 2 Ohmit SE, Petrie JG, Malosh RE. et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56 (10) 1363-1369
    CrossrefPubMedGoogle Scholar
  • 3 Willmott M, Nicholson A, Busse H, MacArthur GJ, Brookes S, Campbell R. Effectiveness of hand hygiene interventions in reducing illness absence among children in educational settings: a systematic review and meta-analysis. Arch Dis Child 2016; 101 (01) 42-50
    CrossrefPubMedGoogle Scholar
  • 4 Pedro CR, Freitas PP, Papoila AL. et al. Respiratory diseases in children attending kindergartens: health-related variables and mothers' psychological, parental, and marital functioning. Health Psychol Open 2017; 4 (02) 2055102917724334
    CrossrefPubMedGoogle Scholar
  • 5 Laursen RP, Larnkjær A, Ritz C, Hauger H, Michaelsen KF, Mølgaard C. Probiotics and child care absence due to infections: a randomized controlled trial. Pediatrics 2017; 140 (02) e20170735
    CrossrefPubMedGoogle Scholar
  • 6 Schmidt WP, Pebody R, Mangtani P. School absence data for influenza surveillance: a pilot study in the United Kingdom. Euro Surveill 2010; 15 (03) 19467
    CrossrefPubMedGoogle Scholar
  • 7 Slack-Smith LM, Read AW, Stanley FJ. A prospective study of absence for illness and injury in childcare children. Child Care Health Dev 2002; 28 (06) 487-494
    CrossrefPubMedGoogle Scholar
  • 8 de Hoog MLA, Venekamp RP, van der Ent CK. et al. Impact of early daycare on healthcare resource use related to upper respiratory tract infections during childhood: prospective WHISTLER cohort study. BMC Med 2014; 12: 107
    CrossrefPubMedGoogle Scholar
  • 9 McLean HQ, Peterson SH, King JP, Meece JK, Belongia EA. School absenteeism among school-aged children with medically attended acute viral respiratory illness during three influenza seasons, 2012-2013 through 2014-2015. Influenza Other Respir Viruses 2017; 11 (03) 220-229
    CrossrefPubMedGoogle Scholar
  • 10 Azor-Martinez E, Garcia-Mochon L, Lopez-Lacort M. et al. Child care center hand hygiene programs' cost-effectiveness in preventing respiratory infections. Pediatrics 2021; 148 (06) e2021052496
    CrossrefPubMedGoogle Scholar
  • 11 Brooks F. The link between pupil health and wellbeing and attainment: A briefing for head teachers, governors and staff in education settings. 2014 . Accessed May 12, 2022 at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/370686/HT_briefing_layoutvFINALvii.pdf
    PubMedGoogle Scholar
  • 12 Worrall G. There's a Lot of It about: Acute Respiratory Infection in Primary Care. Abingdon, Engl: Radcliffe Publishing Ltd; 2006
    Google Scholar
  • 13 Kinkade S, Long NA. Acute bronchitis. Am Fam Physician 2016; 94 (07) 560-565
    PubMedGoogle Scholar
  • 14 Thompson M, Vodicka TA, Blair PS, Buckley DI, Heneghan C, Hay AD. TARGET Programme Team. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013; 347: f7027
    CrossrefPubMedGoogle Scholar
  • 15 Singh A, Avula A, Zahn E. Acute bronchitis [Updated May 8, 2022]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022
    Google Scholar
  • 16 Kern WV, Kostev K. Prevalence of and factors associated with antibiotic prescriptions in patients with acute lower and upper respiratory tract infections - a case-control study. Antibiotics (Basel) 2021; 10 (04) 455
    CrossrefPubMedGoogle Scholar
  • 17 Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician 2010; 82 (11) 1345-1350
    PubMedGoogle Scholar
  • 18 Llor C, Bjerrum L. Antibiotic prescribing for acute bronchitis. Expert Rev Anti Infect Ther 2016; 14 (07) 633-642
    CrossrefPubMedGoogle Scholar
  • 19 Harris AM, Hicks LA, Qaseem A. High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2016; 164 (06) 425-434
    CrossrefPubMedGoogle Scholar
  • 20 Nash DR, Harman J, Wald ER, Kelleher KJ. Antibiotic prescribing by primary care physicians for children with upper respiratory tract infections. Arch Pediatr Adolesc Med 2002; 156 (11) 1114-1119
    CrossrefPubMedGoogle Scholar
  • 21 Lucas PJ, Cabral C, Hay AD, Horwood J. A systematic review of parent and clinician views and perceptions that influence prescribing decisions in relation to acute childhood infections in primary care. Scand J Prim Health Care 2015; 33 (01) 11-20
    CrossrefPubMedGoogle Scholar
  • 22 National Institute for Health and Care Excellence (NICE). Respiratory Tract Infections - Antibiotic Prescribing. Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care. London: National Institute for Health and Clinical Excellence; 2008
    Google Scholar
  • 23 Fleming DM, Elliot AJ. The management of acute bronchitis in children. Expert Opin Pharmacother 2007; 8 (04) 415-426
    CrossrefPubMedGoogle Scholar
  • 24 Witte K, Koch E, Volk H-D, Wolk K, Sabat R. The Pelargonium sidoides extract EPs® 7630 drives the innate immune defense by activating selected MAP kinase pathways in human monocytes. PLoS One 2015; 10 (09) e0138075
    CrossrefPubMedGoogle Scholar
  • 25 Witte K, Koch E, Volk H-D, Wolk K, Sabat R. The herbal extract EPs® 7630 increases the antimicrobial airway defense through monocyte-dependent induction of IL-22 in T cells. J Mol Med (Berl) 2020; 98 (10) 1493-1503
    CrossrefPubMedGoogle Scholar
  • 26 Bao Y, Gao Y, Koch E, Pan X, Jin Y, Cui X. Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis. Phytomedicine 2015; 22 (04) 504-509
    CrossrefPubMedGoogle Scholar
  • 27 Michaelis M, Doerr HW, Cinatl Jr J. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine 2011; 18 (05) 384-386
    CrossrefPubMedGoogle Scholar
  • 28 Roth M, Fang L, Stolz D, Tamm M. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One 2019; 14 (02) e0210702
    CrossrefPubMedGoogle Scholar
  • 29 Papies J, Emanuel J, Heinemann N. et al. Antiviral and immunomodulatory effects of Pelargonium sidoides DC. Root extract EPs® 7630 in SARS-CoV-2-infected human lung cells. Front Pharmacol 2021; 12: 757666
    CrossrefPubMedGoogle Scholar
  • 30 Papies J, Emanuel J, Heinemann N. et al. Corrigendum: antiviral and immunomodulatory effects of Pelargonium sidoides DC. Root extract EPs® 7630 in SARS-CoV-2-infected human lung cells. Front Pharmacol 2021; 12: 814452
    CrossrefPubMedGoogle Scholar
  • 31 Brendler T, Al-Harrasi A, Bauer R. et al. Botanical drugs and supplements affecting the immune response in the time of COVID-19: implications for research and clinical practice. Phytother Res 2021; 35 (06) 3013-3031
    CrossrefPubMedGoogle Scholar
  • 32 Matthys H, Köhler S, Kamin W. Safety and tolerability of EPs® 7630 in clinical trials. Adv Pharmacoepidemiol Drug Saf 2013; 02 (04) 142
    PubMedGoogle Scholar
  • 33 Kamin W, Funk P, Seifert G, Zimmermann A, Lehmacher W. EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisited. Curr Med Res Opin 2018; 34 (03) 475-485
    CrossrefPubMedGoogle Scholar
  • 34 Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Phytomedicine 2008; 15 (05) 378-385
    CrossrefPubMedGoogle Scholar
  • 35 Agbabiaka TB, Guo R, Ernst E. Erratum to “Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis”. . [Phytomedicine 15 (2008) 378–385] Phytomedicine 2009; 16 (08) 798-799
    CrossrefPubMedGoogle Scholar
  • 36 Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013; (10) CD006323
    PubMedGoogle Scholar
  • 37 Matthys H, Lehmacher W, Zimmermann A, Brandes J, Kamin W. EPs® 7630 in acute respiratory tract infections – a systematic review and meta-analysis of randomized clinical trials. J Lung Pulm Respir Res 2016; 3 (01) 4-15
    CrossrefPubMedGoogle Scholar
  • 38 Schapowal A, Dobos G, Cramer H. et al. Treatment of signs and symptoms of the common cold using EPs 7630 - results of a meta-analysis. Heliyon 2019; 5 (11) e02904
    CrossrefPubMedGoogle Scholar
  • 39 Wopker PM, Schwermer M, Sommer S. et al. Complementary and alternative medicine in the treatment of acute bronchitis in children: a systematic review. Complement Ther Med 2020; 49: 102217
    CrossrefPubMedGoogle Scholar
  • 40 Seifert G, Brandes-Schramm J, Zimmermann A, Lehmacher W, Kamin W. Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections. BMC Pediatr 2019; 19 (01) 119
    CrossrefPubMedGoogle Scholar
  • 41 Seifert G, Funk P, Reineke T, Lehmacher W. Influence of EPs® 7630 on antipyretic comedication and recovery from acute tonsillopharyngitis in children: a meta-analysis of randomized, placebo-controlled, clinical trials. J Ped Inf Dis 2021; 16 (03) 122-128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med 2018; 11: 91-98
    CrossrefPubMedGoogle Scholar
  • 43 Ulbricht C, Abrams TR, Conquer J. et al. An evidence-based systematic review of umckaloabo (Pelargonium sidoides) by the Natural Standard Research Collaboration. J Diet Suppl 2010; 7 (03) 283-302
    CrossrefPubMedGoogle Scholar
  • 44 Kamin W, Lehmacher W, Zimmermann A. et al. Treatment of sore throat and hoarseness with Pelargonium sidoides extract EPs 7630: a meta-analysis. Pharmadvances 2022; 4 (02) 88-103
    PubMedGoogle Scholar
  • 45 Kardos P, Lehmacher W, Zimmermann A. et al. Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials. Multidiscip Respir Med 2022; 17: 868
    CrossrefPubMedGoogle Scholar
  • 46 Matthys H, Funk P, Zimmermann A, Lehmacher W. Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysis. Multidiscip Respir Med 2023; 18 (01) 914
    PubMedGoogle Scholar
  • 47 Lehrl S, Kardos P, Matthys H, Kamin W. Corrigendum: validation of a clinical instrument for measuring the severity of acute bronchitis in children – the BSS-ped. Open Respir Med J 2018; 12 (01) 81-82
    CrossrefPubMedGoogle Scholar
  • 48 Lehrl S, Matthys H, Kamin W, Kardos P. The BSS - a valid clinical instrument to measure the severity of acute bronchitis. J Lung Pulm Respir Res 2014; 1 (03) 72-80
    CrossrefPubMedGoogle Scholar
  • 49 Lehrl S, Kardos P, Matthys H, Kamin W. Validation of a clinical instrument for measuring the severity of acute bronchitis in children - The BSS-ped. Open Respir Med J 2018; 12: 50-66
    CrossrefPubMedGoogle Scholar
  • 50 Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 2003; 10 (Suppl. 04) 7-17
    CrossrefPubMedGoogle Scholar
  • 51 Matthys H, Heger M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr Med Res Opin 2007; 23 (02) 323-331
    CrossrefPubMedGoogle Scholar
  • 52 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 53 Review Manager (RevMan). Version 5.4 [Computer Program]. The Nordic Cochrane Centre, The Cochrane Collaboration; 2020
    PubMedGoogle Scholar
  • 54 Kamin W, Maydannik V, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther 2010; 48 (03) 184-191
    CrossrefPubMedGoogle Scholar
  • 55 Kamin W, Ilyenko LI, Malek FA, Kieser M. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int 2012; 54 (02) 219-226
    CrossrefPubMedGoogle Scholar
  • 56 Birnbaum H, Morley M, Leong S, Greenberg P, Colice G. Lower respiratory tract infections: impact on the workplace. PharmacoEconomics 2003; 21 (10) 749-759
    CrossrefPubMedGoogle Scholar
  • 57 Haidvogl M, Heger M. Treatment effect and safety of EPs 7630-solution in acute bronchitis in childhood: report of a multicentre observational study. Phytomedicine 2007; 14 (Suppl. 06) 60-64
    CrossrefPubMedGoogle Scholar
  • 58 Kamin W, Behre U, Helm K, Reling B, Funk P, Malek FA. Safety of Pelargonium extract EPs 7630 in young children with acute bronchitis. Front Pediatr 2023; 11: 1107984
    CrossrefPubMedGoogle Scholar
  • 59 Cooper HM. Research synthesis and meta-analysis: a step-by-step approach. Applied Social Research Methods Series. 4 ed. Thousand Oaks, Calif.: SAGE Publications, Inc.; 2009
    Google Scholar
  • 60 Van den Noortgate W, López-López JA, Marín-Martínez F, Sánchez-Meca J. Three-level meta-analysis of dependent effect sizes. Behav Res Methods 2013; 45 (02) 576-594
    CrossrefPubMedGoogle Scholar